Clinical Trials in Tennessee

Showing 6941-6960 of 20,239 trials

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

NCT03421353

This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with advanced, solid tumours and subsequently in patients with non-small-cell lung cancer (NSCLC)

Advanced Solid Tumours

AstraZeneca76 participantsStarted Feb 2018

Lafayette, Indiana, United States • Oklahoma City, Oklahoma, United States • Nashville, Tennessee, United States +3 more locations

COMPLETEDPhase 329 miles

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

NCT02989857

Study AG120-C-005 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of orally administered AG-120. Participants, all personnel involved in the evaluation of participants' response to treatment (e.g., Investigators, study coordinators, study pharmacists), and designated Sponsor team members will be blinded to study treatment. Participants are required to have a histologically-confirmed diagnosis of isocitrate dehydrogenase-1 (IDH1) gene-mutated cholangiocarcinoma that is not eligible for curative resection, transplantation, or ablative therapies prior to enrollment. IDH1 mutation testing will be performed at participating investigative sites. Participants must have progression of disease and have received at least 1 but not more than 2 prior treatment regimens for advanced disease (nonresectable or metastatic). All participants must have received either a gemcitabine or a 5 fluorouracil (5-FU) based chemotherapy regimen.

Advanced CholangiocarcinomaMetastatic Cholangiocarcinoma

Institut de Recherches Internationales Servier187 participantsStarted Feb 2017

Scottsdale, Arizona, United States • Duarte, California, United States • Irvine, California, United States +46 more locations

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

Find Trials by Condition in Tennessee

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Otoacoustic Emission Suppression Study

Physiologic Pacing Registry

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

CardioFocus HeartLight Post-Approval Study

Situation Awareness Incorporating Multidisciplinary Teams Reduce Arrests In the Pediatric ICU

Pilot Randomized Trial With Flecainide in ARVC Patients

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Cefadroxil 500 mg Capsules Under Fasting Conditions

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping